TrialOncotarget2016
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Pin Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
49 papers cite it
this paperpooled ittrialcites it